Wijnsma KL, et al. - Researchers determined the safety as well as efficacy of a restrictive treatment regimen in 20 patients with atypical haemolytic uremic syndrome (aHUS) in this retrospective study. They analyzed clinical, diagnostic and follow-up data of all aHUS patients who presented in the Radboud University Medical Center, Nijmegen, The Netherlands, between 2012 and 2016 and received eculizumab. Eculizumab was tapered in all and stopped in 17 patients. Findings demonstrated the safety and efficacy of a restrictive eculizumab regimen in aHUS. The recurrence of aHUS was reported in five patients and no clinical sequela such as proteinuria or progressive kidney dysfunction was detected subsequently. This treatment strategy saved ~€11.4 million.